Navigation Links
Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Date:8/13/2012

CARLSBAD, Calif., Aug. 13, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has delivered a notice of redemption relating to all of its outstanding 2 ⅝% Convertible Subordinated Notes due 2027 (the "2027 Notes") at a redemption price of 100.75% of the principal amount thereof.  As of August 13, 2012, $162,500,000 aggregate principal amount of the 2027 Notes was outstanding.  The 2027 Notes will be redeemed on September 12, 2012 unless earlier converted.  The CUSIP Numbers of the 2027 Notes are 464337AD6 and 464337AE4.

The 2027 Notes are convertible at any time prior to 5:00 p.m. Eastern Time, September 11, 2012 at a rate of 68.3761 shares of common stock per $1,000 principal amount of the 2027 Notes converted.  If any 2027 Notes are surrendered for conversion, the conversion will be settled in cash.

Wells Fargo Bank, N.A., the trustee for the 2027 Notes, is delivering a Notice of Redemption to all registered holders of the 2027 Notes on August 13, 2012.  Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2027 Notes may be obtained from the Wells Fargo Bank, N.A., by calling (800) 344-5128.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
2. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
3. Intercept Pharmaceuticals Closes $30 Million Series C Financing
4. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
5. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
7. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
8. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
10. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
11. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising Phase 1/2 ... mda-7/IL-24 tumor,suppressor agent, in patients with advanced solid ... today at the,annual meeting of the American Society ... INGN 241 induced killing in all treated,tumors, including ...
... Company Planning to Initiate Phase 2 Trials ... in Q307 -, SOUTH SAN FRANCISCO, Calif., ... , a,biopharmaceutical company focused on oncology, today ... of two Phase 1,dose-escalating trials of picoplatin, ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Kan., Jan. 28 Fort Dodge Animal Health,a ... the American Association of Equine,Practitioners (AAEP) recently announced ... raise awareness regarding the health of horses.,Americashealthyhorse.com provides ... The America,s Healthy Horse Web site will aide ...
... -- The Cystic Fibrosis Foundation reported today that key ... including lung function and nutritional status -- are rising ... fact, the outlook for people with CF continues to ... accelerating due to quality improvement programs spearheaded by the ...
... To support,Pennsylvanians who made a New Year,s resolution ... announced that Governor Edward G.,Rendell has proclaimed Jan. 28 ... "Determined to Quit Week is all about motivating Pennsylvanians ... Secretary of,Health Dr. Calvin B. Johnson. "For anyone who ...
... to Expand Profile with Area Representatives, TAMPA, ... leading study program, announces a new program to ... Area,Representatives will travel to massage schools nationwide to ... so comprehensive that,Massage Prep guarantees passage of the ...
... ... Presenting at the UBS Global Healthcare Services Conference on Tuesday, ... February 12, 2008, CINCINNATI, Jan. ... the,LasikPlus brand, announced today upcoming investment community events., Fourth Quarter & Full-Year 2007 ...
... Russian women who smoke has more than doubled since the ... In 1992, seven per cent of women smoked, compared to ... the number of men who smoke has risen from 57 ... the study, published in the journal Tobacco Control, blame the ...
Cached Medicine News:Health News:Fort Dodge Animal Health and the American Association of Equine Practitioners Launch Educational Web Site 2Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
... provides surgeons with brighter, crisper, magnified views ... for many minimally invasive spine procedures. It ... point of contact. The first graphical touchscreen ... allows intuitive user guidance similar to that ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: